Welcome! We regret to inform you that the Injury Board National News Desk has been discontinued. Feel free to browse around and enjoy our previously published articles, or visit The Injury Blog Network for the latest in personal injury news.

No Suicide Risk Found With Singulair- FDA

Posted by Jane Akre
Wednesday, January 14, 2009 11:53 AM EST
Category: Major Medical, Protecting Your Family
Tags: FDA and Prescription Drugs, Allergies, Singulair, Merck, Asthma, Dangerous Drugs, Suicides

Singulair not found linked to suicide by FDA reviewers looking at Merck data.

LEARN MORE

 

IMAGE SOURCE: WikiMedia Commons/ cat allergy/Martin Bahmann

 

The probe is still in its early stages, but federal health officials do not believe that asthma drugs are tied to suicide.

The Food and Drug Administration (FDA) looked at Merck’s Singulair and found that Merck data do not show any association. Dozens of company studies were submitted by Merck which says it has cooperated with the FDA and turned over extensive company records.

Last March a handful of reports indicated that taking Singulair, Astra Zeneca PLC’s Accolate, and Zyflo could result in suicidal behavior and mood changes.

Merck stresses that none of the 11,000 patients enrolled in their drug trials has killed themselves and the FDA says this is an effort to inform the public, no casual relationship has been established between the drug and suicide.

Recently the drug maker was required to update its label warning of suicidal thinking and behavior.

The label now reads: "The following additional adverse reactions have been reported in post-marketing use: Psychiatric disorders: agitation including aggressive behavior, anxiousness, dream abnormalities and hallucinations, depression, insomnia, irritability, restlessness, suicidal thinking and behavior (including suicide), tremor."

An Albany, New York area couple clamed their 15-year-old’s death last August on his switch to the allergy medication Singulair from Allegra. But Merck stresses tis and others are anecdotal reports from consumers, not data that the company has observed.

In an effort to have an “Early Communication” with the public about any safety concerns, the FDA decided to act more quickly to notify the public before they draw any conclusions.

That is in response to criticism that the FDA acted too slowly in informing the public about another Merck medication, Vioxx, which was eventually removed from the market after it caused thousands of heart attacks and strokes.  

Further studies into mood disorders resulting from the asthma therapies will continue. 

Singulair is a best seller for Merck with sales exceeding $4 billion. #


No Comments

Comments for this article are closed.

About the National News Desk

Our mission is to seek the complete truth and provide a full and fair account of the events and issues that surround personal safety, accident prevention, and injury recovery.  We are committed to serving the public with honesty and integrity in these efforts.

Hurt in an accident? Contact an Injury Board member

Subscribe to Blog Updates

Enter your email address if you would like to receive email notifications when comments are made on this post.

Email address

Subscribe

RSS Feed

Add the National News Desk to your favorite RSS reader

Add to Google Reader Add to myYahoo Add to myMSN Add to Bloglines Add to Newsgator Add to Netvibes Add to Pageflakes